$PDS Biotechnology (PDSB.US)$PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024 2 MINUTES AGO, 7:00 AM EDT VIA GLOBENEWSWIRE Median Overall Survival remains at 30 months; Objective Response Rate of 36% and Disease Control Rate of 77% 11/53 (21%) of patients experienced 90-100% tumor shrinkage
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more